Howard S Hochster MD

Oncology•New Brunswick, NJ

Gastrointestinal Cancer, Hematologic Oncology

Distinguished Professor of Medicine, Rutgers RWJ School of Medicine

Join to View Full Profile

195 Little Albany StreetRoom 2004New Brunswick, NJ 08901
Phone+1 732-235-5912
Fax+1 732-235-6797

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1983 - 1986
NYU Grossman School of MedicineResidency, Internal Medicine, 1980 - 1983
Yale School of MedicineClass of 1980

Certifications & Licensure

NJ State Medical License 2018 - 2025
CT State Medical License 2010 - 2018
NY State Medical License 1981 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly, 2005-2019
America's Top Doctors Castle Connolly, 2004-2019
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2002-2007, 2011-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Join now to see all

Clinical Trials

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Start of enrollment: 2008 Sep 01
Active, not recruiting
The Effect of Sorafenib on Portal Pressure Start of enrollment: 2011 Aug 01
Completed
Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer Start of enrollment: 2014 Jul 01
Completed
Phase 1
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer Start of enrollment: 2017 May 11
Completed
Phase 2
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer Start of enrollment: 2019 Feb 12
ACTIVE_NOT_RECRUITING
PHASE2
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy Start of enrollment: 2022 Jul 29
Recruiting
Phase 2
Roles: Contact
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery Start of enrollment: 2022 May 03
Recruiting
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer Start of enrollment: 2022 Mar 14
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer Start of enrollment: 2023 May 17
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505.
Sameer H Patel, Sarah Colby, Davendra Sohal, Katherine A Guthrie, Lisa A Kachnic
Cancer. 2025-02-15
1 citations
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Canc...
Rachna T Shroff, Gentry King, Sarah Colby, Aaron J Scott, Mitesh J Borad
Journal of Clinical Oncology. 2025-02-10
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.
Patrick M Boland, Heinz-Josef Lenz, Kristen K Ciombor, Vaia Florou, Michael J Pishvaian
Investigational New Drugs. 2025-02-01

Journal Articles

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Andrea Wang-Gillam, Howard S Hochster, JAMA Oncology
Association of Diet Quality with Survival Among People with Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial
Kimmie Ng, Chloe Atreya, Howard S Hochster, James N Atkins, Richard M Goldberg, Charles D Blanke, Jeffrey A Meyerhardt, JAMA Network Open
Antiangiogenesis in Early-Stage Colon Cancer—Microscopically Busted
Howard Hochster, MD, JAMA Network Open

Abstracts/Posters

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group
Howard Hochster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Yale Cancer Center Evening Oncology Series: Gastrointestinal Cancers
Yale CME, New Haven, Connecticut - 9/20/2012

Press Mentions

How Many Patients in Early Cancer Trials Get Drugs Ultimately Approved by FDA?March 7th, 2025
A Good Number of Cancer Patients in Mid-Stage Trials Get Drugs Later ApprovedFebruary 25th, 2025
You Can Now Get a Blood Test to Screen for Colorectal CancerAugust 2nd, 2024
Join now to see all